SCHEMBL2356348

SCHEMBL2356348

O=C(O)Nc1nc2ccc(C(=O)c3ccccc3C(=O)Nc3cccc(Br)c3)cc2[nH]1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAF1 P04049 5/20 0.59
▸ BRAF P15056 5/20 0.59
▸ KMT2A Q03164 2/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ NPC1 O15118 1/20 0.51
▸ RAB9A P51151 1/20 0.51
▸ ALDH1A1 P00352 4/20 0.51
▸ CYP2C9 P11712 3/20 0.51
▸ MAPT P10636 3/20 0.51
▸ CYP1A2 P05177 2/20 0.51
▸ KDM4E B2RXH2 2/20 0.51
▸ CYP2C19 P33261 2/20 0.51
▸ CYP2D6 P10635 1/20 0.51
▸ MAPK1 P28482 1/20 0.51
▸ NPSR1 Q6W5P4 1/20 0.51
▸ HTT P42858 3/20 0.49
▸ ABL1 P00519 3/20 0.49
▸ LMNA P02545 2/20 0.49
▸ KDR P35968 2/20 0.49
▸ ABCC4 O15439 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2357955 0.89 RAF1 (0.63) RAF1BRAFKMT2AMEN1NPC1
SCHEMBL3473662 0.88 RAF1 (0.59) RAF1BRAFKMT2ARAB9AALDH1A1
SCHEMBL3471881 0.88 RAF1 (0.59) RAF1BRAFKMT2ANPC1RAB9A
SCHEMBL3475822 0.88 RAF1 (0.59) RAF1BRAFKMT2AMEN1NPC1
SCHEMBL3474868 0.87 RAF1 (0.60) RAF1BRAFKMT2ANPC1RAB9A
SCHEMBL2297139 0.86 RAF1 (0.57) RAF1BRAFKMT2ARAB9AALDH1A1
SCHEMBL1791971 0.86 RAF1 (0.64) RAF1BRAFKMT2AMEN1NPC1
SCHEMBL1792255 0.86 RAF1 (0.57) RAF1BRAFMAPTKDRTEK
SCHEMBL2299280 0.86 RAF1 (0.57) RAF1BRAFKMT2AMEN1NPC1
SCHEMBL1791715 0.86 RAF1 (0.59) RAF1BRAFKMT2ARAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP claimed
US-7846959-B2 Raf modulators and methods of use EXELIXIS, INC. (US) 2010-12-07 — — US claimed
WO-2009017838-A2 COMBINATIONS OF JAK-2 INHIBITORS AND OTHER AGENTS EXELIXIS, INC. (US) 2009-02-05 — — WO claimed
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP disclosed
US-7999006-B2 Anticancer agents; mitogen-activated protein kinases (MEK) EXELIXIS, INC. (US) 2011-08-16 — — US disclosed
Send feedback